Encapsulated cells producing retroviral vectors for in vivo gene transfer

Journal of Gene Medicine

Volumn 4, Issue 2, 2002, Pages 150-160

  Saller, Robert M ^a,b   Indraccolo, Stefano ^c,d   Coppola, Vincenzo ^d   Esposito, Giovanni ^d   Stange, Jan ^e   Mitzner, Steffen ^e   Amadori, Alberto ^d   Salmons, Brian ^f   Günzburg, Walter H ^a,g  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b Bavarian Nordic GmbH   (Germany)

^c IST Viral and Molecular Oncology Section   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF ROSTOCK   (Germany)

^f Austrian Nordic Biotherapeutics AG   (Austria)

^g UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

Cellulose sulphate; Encapsulation; In vivo delivery; Retroviral vectors

Indexed keywords

CELLULOSE SULFATE; EOSIN; HEMATOXYLIN; RETROVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL BASED GENE THERAPY; CELL CULTURE; FEASIBILITY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LYMPHOID CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MAMMARY GLAND; MICROENCAPSULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRION; VIRUS TITRATION; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; BREAST; CELL SEPARATION; CELL STRAIN 3T3; COCULTURE; DRUG FORMULATION; FLOW CYTOMETRY; GENE TRANSFER; GENE VECTOR; GENETICS; METABOLISM; MOUSE MUTANT; NEWBORN; POLYMERASE CHAIN REACTION; RETROVIRUS; TIME;

3T3 CELLS; ANIMALS; ANIMALS, NEWBORN; BREAST; CELL SEPARATION; COCULTURE TECHNIQUES; DRUG COMPOUNDING; FEMALE; FLOW CYTOMETRY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; MICE; MICE, INBRED BALB C; MICE, SCID; MODELS, GENETIC; POLYMERASE CHAIN REACTION; RETROVIRIDAE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS;

EID: 0036518340     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.257     Document Type: Article

References (37)

1. Gunzburg WH, Saller RM, Salmons B. Retroviral vectors directed to pre-defined cell types for gene therapy. Biologicals 1995; 23: 5-12.
2. McCormack JE, Edwards W, Sensintaffer J, et al. Factors affecting long-term expression of a secreted transgene product after intravenous administration of a retroviral vector. Mol Ther 2001; 3: 516-525.
3. Tait DL, Obermiller PS, Hatmaker AR, Redlin-Frazier S, Holt JT. Ovarian cancer BRCA1 gene therapy: phase I and II trial differences in immune response and vector stabillity. Clin Cancer Res 1999; 5: 1708-1714.
4. Paul RW, Morris D, Hess BW, Dunn J, Overell RW. Increased viral titre through concentration of viral harvests from retroviral packaging lines. Hum Gene Ther 1993; 4: 609-615.
5. Chuck AS, Palsson BO. Consistent and high rates of gene transfer can be obtained using flow-through transduction over a wide range of retroviral titres. Hum Gene Ther 1996; 7: 743-750.
6. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumours. Science 1992; 256: 1550-1552.
7. Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfield EH. In situ retroviral-mediated gene transfer for the treatment of brain tumours in rats. Cancer Res 1993; 53: 83-88.
8. Chang TM, Prakash S. Therapeutic uses of microencapsulated genetically engineered cells. Mol Med Today 1998; 4: 221-227.
9. Tai IT, Sun AM. Microencapsulation of recombinant cells: a new delivery system for gene therapy. FASEB J 1993; 7: 1061-1069.
10. Peirone MA, Delaney K, Kwiecin J, Fletch A, Chang PL. Delivery of recombinant gene product to canines with non-autologous microencapsulated cells. Hum Gene Ther 1998; 9: 195-206.
11. Lui HW, Ofosu FA, Chang PL. Expression of human Factor IX by microencapsulated recombinant fibroblasts. Hum Gene Ther 1993; 4 640-653.
12. Hortelano G, Al-Hendy A, Ofosu FA, Chang PL. Delivery of human Factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of haemophilia B. Blood 1996; 87: 5095-5103.
13. Springer ML, Hortelano G, Bouley DM, Wong J, Kraft PE, Blau HM. Induction of angiogenesis by implantation of encapsulated primary myoblasts expressing vascular endothelial growth factor. J Gene Med 2000; 2: 279-288.
14. Sun Y, Ma X, Zhou D, Vacek I, Sun AM. Normalisation of diabetes in spontaneously diabetic cynomologous monkeys by xenografts of microencapsulated porcine islets without immunosuppression. J Clin Invest 1998; 98: 1417-1422.
15. Winn SR, Hammang JP, Emerich DF, Lee A, Palmiter RD, Baetge EE. Polymer-encapsulated cells genetically modified to secrete human nerve growth factor promote the survival of axotomized septal cholinergic neurons. Proc Natl Acad Sci U S A 1994; 91: 2324-2328.
16. Aebischer P, Schluep M, Deglon N, et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nature Med 1996; 2 696-699.
17. Stange J, Mitzner S, Dautzenberg H, et al. Prolonged biochemical and morphological stability of encapsulated liver cells - a new method. Biomat Art Cells Immob Biotech 1993; 21: 343-352.
18. Dautzenberg H, Schuldt U, Grasnick G, et al. Development of cellulose sulphate-based polyelectrolyte complex microcapsules for medical applications. Ann N Y Acad Sci 1999; 18: 875:46-63.
19. Jainchill JL, Anderson SA, Todaro GJ. Murine sarcoma and leukaemia viruses: assay using clonal lines of contact-inhibited mouse cells. J Virol 1969; 4: 549-553.
20. Crandell RA, Fabricant CG, Nelson-Rees WA. Development, characterization, and virus susceptibility of a feline (Felis catus renal cell line (CRFK). In vitro 1973; 9: 176-185.
21. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 1986; 6: 2895-2902.
22. Price J, Turner D, Cepko C. Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. Proc Natl Acad Sci U S A 1987; 84: 156-160.
23. Cepko CL. Immortalisation of neural cells via retrovirus-mediated oncogene transduction. Annu Rev Neurosci 1989; 12: 47-65.
24. Klein D, Indraccolo S, von Rombs K, Amadori A, Salmons B, Günzburg WH. Rapid identification of viable retrovirus transduced cells using the green fluorescent protein as a marker. Gene Ther 1997; 4: 1256-1260.
25. Salmons B, Knedlitschek G, Kennedy N, Groner B, Ponta H. The endogenous mouse mammary tumour virus locus Mtv-8 contains a defective envelope gene. Virus Res 1986; 4: 377-389.
26. Indraccolo S, Gunzburg WH, Leib-Mosch C, Erfle V, Salmons B. Identification of three human sequences with viral superantigen-specific primers. Mam Gen 1995; 6: 339-344.
27. Welsh RM, Cooper NR, Jensen FC, Oldstone MBA. Human serum lyses RNA tumour viruses. Nature 1975; 257: 612-614.
28. Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK. High-titre packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995; 69: 7430-7436.
29. Takeuchi Y, Cosset F-LC, Lachmann PJ, Okada H, Weiss RA, Collins MKL. Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol 1994; 68: 8001-8007.
30. Rother RP, Squinto SP, Mason JM, Rollins SA. Protection of retroviral vector particles in human blood through complement inhibition. Hum Gene Ther 1995; 6: 429-435.
31. Pelegrin M, Marin M, Noel D, et al. Systemic long-term delivery of antibodies in immunocompetent animals using cellulose sulphate capsules containing antibody-producing cells. Gene Ther 1998; 5: 828-834.
32. Pelegrin M, Marin M, Oates A, et al. Immunotherapy of a viral disease by in vivo production of therapeutic monoclonal antibodies. Hum Gene Ther 2000; 11: 1407-1415.
33. Breun S, Salmons B, Günzburg WH, Baumann J. Protection of MLV-vectors from human complement. Biochem Biophys Res Commun 1999; 264: 1-5.
34. Okada N, Miyamoto H, Yoshioka T, et al. Immunological studies of SK2 hybridoma cells microencapsulated with alginate-poly (L)lysine-alginate (APA) membrane following allogeneic transplantation. Biochem Biophys Res Commun 1997; 230: 524-527.
35. Vigna E, Naldini L. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2000; 2: 308-316.
36. Janka I, Günzburg WH, Brem G, Erfle V, Salmons B. Subretroviral particles as gene transfer vectors that by-pass retrovirus receptor interaction restrictions. Biochem Mol Biol Int 1993; 31 349-357.
37. Couffinhal T, Kearney M, Sullivan A, Silver M, Tsurumi Y, Isner JM. Histochemical staining following LacZ gene transfer underestimates transfection efficiency. Hum Gene Ther 1997; 8 929-934.